CAMP4 THERAPEUTICS CORPORATION (CAMP) - GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - CAMP4 THERAPEUTICS CORP

Explicit Guidance:

• Clinical Milestones: First patients for the SYNGAP1 program (CMP-002) expected to be dosed by the end of the current year; first top-line data anticipated in the first half of 2028.
• Cash Position & Runway: $124 million in cash as of Q3, sufficient to fund operations through the end of 2028 to achieve SYNGAP1 milestones and advance the SHANK3 program.
• Share Count/Dividends: No specific forward-looking guidance provided regarding capital structure changes, dividends, or buybacks.

Business-Segment Outlook:

• Lead Asset (SYNGAP1): As the first company with a disease-modifying approach for SYNGAP1; target population estimated at 10,000+ patients in the U.S. (potentially higher); Phase I/II global study initiated with 3-to-1 randomization and a control arm.
• Second Asset (SHANK3): Program for Phelan-McDermid syndrome targeting 45,000 U.S. patients; expected to utilize a "rinse, wash, repeat" strategy following SYNGAP1 success; preclinical data mirrors SYNGAP1 results.
• Platform Expansion: Technology broadly applicable to any tissue/disease requiring gene upregulation; currently focusing on CNS haploinsufficient diseases but expanding via partnerships (e.g., GSK partnership announced late 2025 to target large CNS and kidney indications).
• Pipeline Inflection Points: Success in SYNGAP1 clinical data is expected to significantly increase the probability of success for SHANK3 and undisclosed programs due to the mechanistic consistency of the ASO platform.

Market and Competitive Outlook:

• Competitive Landscape: Described as "pretty sparse" with Camp 4 being "farthest along"; competitors include academic efforts and downstream splice-switching approaches that have not yet moved the needle.
• Competitive Advantage: Unique ability to upregulate all six isoforms of the target gene simultaneously by acting at the transcriptional level, a capability gene therapy and downstream approaches reportedly lack.
• Market Sizing: Management characterizes the commercial opportunity as "massive," comparing the unmet need to Spinal Muscular Atrophy (SMA) and Cystic Fibrosis; anticipates potential for premium pricing given the severity and lack of approved treatments.
• Diagnostic Trends: Diagnostic rates expected to accelerate due to whole-genome screening and genetic panels, reducing the diagnostic odyssey from ~10 years to ~1 year.

Macro / Industry Outlook:

• Regulatory Environment: Expresses strong optimism regarding the FDA's stance on rare diseases and potential for accelerated approval pathways; emphasizes the necessity of a control arm in trial design to facilitate regulatory discussions and approval options.
• Global Development: Study clearance obtained in Australia, Argentina, the UK, and via the EMA; actively engaging with the FDA.
• Industry Trend: Notes a broader pattern where rare diseases evolve from obscurity to "household names" over 3–5 years as awareness and advocacy grow.

Strategic Initiatives:

• Partnerships: GSK partnership (announced late 2025) to target additional large CNS and kidney indications; Camp 4 identifies regulatory RNAs and creates ASOs, handing off to GSK in exchange for milestones and royalties.
• Business Development Strategy: Prioritizing "asset-based" deals (selling specific assets) rather than "platform-based" deals to maintain optionality and value for own assets; open to further discovery deals.
• Trial Design Strategy: Implementing a global Phase I/II multiple ascending dose study with three cohorts (8+ patients each), three doses over three months, six-month follow-up, and a control arm to maximize regulatory optionality.
• Commercial Strategy: Focusing on defining success metrics for a disease with no regulatory precedent; plans to leverage natural history data (1,400+ patient-years) for comparison.

Risks and Headwinds to Outlook:

• Clinical Success Definition: As a "signal-seeking" study with no prior disease-modifying therapy precedent, the specific clinical endpoints for success are not yet defined; regulatory acceptance of the chosen metrics is a key variable.
• Timeline Variability: First data readout is scheduled for H1 2028, but management cautions that while they expect this timeline, "things can happen faster than you think."
• Regulatory Uncertainty: While encouraged by FDA trends, the path to approval (e.g., accelerated vs. standard) is contingent on the specific data generated in the Phase I/II study.
• Disease Complexity: The severity of SYNGAP1 (hundreds of seizures/day, lack of speech) creates high stakes for demonstrating meaningful clinical separation.

Management Tone on the Future:

• Confidence Level: Highly confident in the biology and platform ("feature of the system" that upregulation caps at two-fold); expresses belief in the "massive" value of the company if the SYNGAP1 thesis proves correct.
• Strategic Hedges: Emphasizes "under-promising and over-delivering" on timelines; maintains a "blind" to protect credibility while waiting for the "cake to be baked."
• Valuation View: Believes the stock is "deeply undervalued" relative to the potential success of SYNGAP1 and the subsequent unlock of value from the broader pipeline.
• Execution Focus: Describes the team as "heads down" with a "tight" spending rate, focusing on execution rather than market messaging until data release.

Miscellaneous:

• No Interim Data: Management explicitly stated no interim safety or pharmacokinetic readouts are expected between now and the first half of 2028, other than general progress updates.
• Mechanism Specificity: Will pursue indication-by-indication due to the genetic specificity of ASOs; basket trials across different diseases are not currently planned as the mechanism targets specific regulatory RNAs for each gene.